This site is intended for healthcare professionals
Drug News

Phase III trial of Libtayo as monotherapy for first-line advanced NSCLC stopped early due to highly significant improvement in overall survival.- Sanofi + Regeneron

Read time: 2 mins
Last updated:28th Jun 2021
Published:28th Apr 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest